Trial Profile
Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Losartan (Primary) ; Raltegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 18 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2014 Planned End Date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 26 May 2012 Companies added in association field as reported by European Clinical Trials Database.